Coadministration of pexidartinib (a CYP3A4 inducer) with delicate CYP3A substrates may perhaps bring on critical therapeutic failures. If concomitant use is unavoidable, boost the CYP3A substrate dosage in accordance with permitted product or service labeling.butorphanol decreases effects of fentanyl by pharmacodynamic antagonism. Avoid or Use Alte